Shosh Merchav, Ph.D, MBA

SENIOR CONSULTANT

Shosh Merchav has been involved in the field of translational research and drug development since the early 80's, both in the Academic as well as Industrial setting. In her latest job at Teva, which she joined in 2006, she headed the Oncology and Cell Therapy Projects Unit at Teva Innovative Ventures, where she was responsible for hands-on supporting and overseeing preclinical to registration phase projects in several investment companies as well as in internal programs, in the fields of oncology (cytotoxics, biologics, cell therapy), heart failure, wound healing, neurodegenerative and peripheral artery disease. Among her roles at Teva, Shosh was also a member of various sourcing evaluation committees for product in-licensing or partnering.

Prior to joining Teva, Dr. Merchav served as General Manager and Director of Research and Operations at ViaCell Singapore Pte. Ltd., which she had established in 2002 as a subsidiary of ViaCell Inc., and managed till 2006.

Before joining the biotech industry, Dr. Merchav held a tenured academic position from 1986 until 2006 at the department of Cell Biology, Rappaport Faculty of Medicine in Technion, Israel, where she established and headed the Experimental Hematopoiesis and Cell Therapy Unit.

Dr. Merchav's translational research activities included Cord Blood Stem Cell Expansion technologies, the latter licensed to Pluristem Inc. Dr. Merchav holds a Ph.D. from Erasmus University in Rotterdam and an MBA degree from Haifa University Business School.